Navigation Links
New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimer's Disease Market
Date:6/17/2009

Sales of Acetylcholinesterase Inhibitors, Which Currently Dominate the Market, Will Decline by $1 Billion from 2008 to 2018, According to a New Report from Decision Resources

WALTHAM, Mass., June 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch and uptake of new anti-amyloid monoclonal antibodies, most notably Elan/Wyeth's bapineuzumab and Eli Lilly's solanezumab, will be the main driver of robust 11 percent annual growth from 2008 to 2018 in the Alzheimer's disease drug market. Other key agents that will drive market growth include Baxter's Gammagard, Eli Lilly's semagacestat, and Pfizer/Medivation's Dimebon.

The new Pharmacor report entitled Alzheimer's Disease finds that bapineuzumab and solanezumab will together garner just over half of the overall Alzheimer's disease market in 2018. While these two monoclonal antibodies are expected to offer superior efficacy over other drugs in the market, their uptake will be initially slow following their launches, owing to potential safety concerns. Nevertheless, bapineuzumab and solanezumab will achieve combined sales of nearly $6 billion in 2018.

The Alzheimer's disease market is currently dominated by acetylcholinesterase inhibitors (AChEIs), all of which only address cognitive symptoms but do not modify the course of the disease. In 2008, sales of these agents for Alzheimer's disease (excluding other forms of dementia) accounted for $2.7 billion in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan--in 2018, they will represent only $1.7 billion in sales, according to the report. This decline will be attributed to increased generic AChEI competition, overall market expansion driven by increases in the drug-treated population and the commercialization of emerging therapies with the potential to modify the progression of the disease.

"Interviewed experts believe that the agents with the most clinical and commercial promise are the anti-beta amyloid monoclonal therapies such as bapineuzumab and solanezumab, which have the potential to slow the rate of neurodegeneration and cognitive decline," said Decision Resources Analyst Matthew Winton, Ph.D. "However, the efficacy and safety of these monoclonal antibodies has yet to be fully established."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.



    For more information, contact:

    Decision Resources                               Decision Resources, Inc.
    Christopher Comfort                              Elizabeth Marshall
    781-296-2597                                     781-296-2563
    ccomfort@dresources.com                          emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Growth in the Parkinsons Disease Drug Market, Fueled by the Launch of Several New Therapies, Will be Offset by Generic Erosion of Key Agents
2. Despite Patent Expiries of Leading Therapies, New Product Launches Will Drive a $4.6 Billion Increase in the Coronary Heart Disease Market
3. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
4. New Poll Finds Most Americans Support Including Treatment for Drug and Alcohol Addiction in National Health Care Reform; All Demographics Report Personal Experience With the Disease
5. Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002
6. New Report Emphasizes Critical Role of Including Early and Preventative Care for Women in Health Care Reform
7. The First High-Performance Sports Water, AquaHydrate, Targets Military Market by Supporting Events Including Mud Run
8. LOHAS Announces Final Program Line-up Including Speakers from Wal-Mart, Coca Cola, MINI, Facebook Causes, Saatchi & SaatchiS, Gaiam and eBay
9. MPR Drug Database Available as a Free Download for Mobile Devices, Including BlackBerry and Palm
10. Coalition Commends Senators Baucus, Grassley for Including Prevention, Wellness of Chronic Disease in Recent Paper on Coverage Policy Options
11. Sen. Max Baucus: Answer 10 Questions About Mandatory Purchase of Health Insurance Including Why the Public Was Excluded From Todays Committee Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... Ariz. (PRWEB) , ... June 28, 2017 , ... ... proud to announce that its 50ml Liquid Stevia Sweet Drops™ have received the ... undergone the verification process from the Non-GMO Project, the only third-party verification for ...
(Date:6/28/2017)... ... June 28, 2017 , ... Eating disorders have the highest ... minutes, at least one person dies as a direct result from an eating disorder ... for qualified treatment providers. The iaedp Foundation meets this challenge by offering what has ...
(Date:6/28/2017)... ... June 28, 2017 , ... Canadian Zeolite ... that a two year study conducted by the University of Saskatchewan in partnership ... in remediating potash brine-impacted groundwater. As a part of the study, batch adsorption ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... of Mike Finnegan to the position of Executive Vice President, Sales and Marketing. ... healthcare technology, telehealth and medical device sales leadership. He has received industry recognition ...
(Date:6/27/2017)... BOSTON, MA (PRWEB) , ... June 27, 2017 , ... ... U.S. Senate bill to repeal and replace the 2010 Patient Protection and Affordable Care ... as compared with what would be expected under current law. , More than 20 ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... 2017 AirXpanders, Inc. (ASX: AXP) (AirXpanders or ... manufacture, sale and distribution of the AeroForm® Tissue Expander ... its commercial roll-out in the United States ... one hundred (100) medical institutions and health systems, located ... needle-free alternative for women who choose reconstructive surgery following ...
(Date:6/7/2017)... 7, 2017 Endo International plc (NASDAQ: ... the Hon. Joseph R. Goodwin , U.S. District ... West Virginia , entered a case management order ... System Products Liability Litigation (the "MDL") that includes a ... provide expert disclosures on specific causation within one hundred ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
Breaking Medicine Technology: